Cheyne Capital Management (UK) LLP - BIOMARIN PHARMACEUTICAL INC ownership

BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Cheyne Capital Management (UK) LLP ownership history of BIOMARIN PHARMACEUTICAL INC
ValueSharesWeighting
Q2 2022$1,486,000
-36.2%
1,500,000
-35.3%
1.26%
-14.5%
Q1 2022$2,330,000
-4.6%
2,320,0000.0%1.47%
-7.8%
Q4 2021$2,442,000
+2.0%
2,320,0000.0%1.59%
+11.6%
Q3 2021$2,395,000
-18.5%
2,320,000
-17.7%
1.43%
+6.7%
Q2 2021$2,938,000
+1.5%
2,820,0000.0%1.34%
-27.1%
Q1 2021$2,895,000
-16.1%
2,820,000
-12.4%
1.84%
+5.1%
Q4 2020$3,452,000
+2.5%
3,220,0000.0%1.75%
+5.0%
Q3 2020$3,368,000
+10.8%
3,220,000
+30.4%
1.66%
-19.0%
Q2 2020$3,040,000
+18.0%
2,470,0000.0%2.05%
-22.6%
Q1 2020$2,576,000
-24.6%
2,470,000
-23.3%
2.65%
+28.2%
Q4 2019$3,416,000
+7.6%
3,220,0000.0%2.07%
+3.3%
Q3 2019$3,176,000
+19.6%
3,220,000
+26.3%
2.00%
+4.0%
Q2 2019$2,656,000
+1.1%
2,550,0000.0%1.93%
-21.5%
Q1 2019$2,626,000
-12.1%
2,550,000
-15.0%
2.46%
-13.0%
Q4 2018$2,986,000
-6.1%
3,000,0000.0%2.82%
+49.4%
Q3 2018$3,179,000
+4.2%
3,000,0000.0%1.89%
-13.1%
Q2 2018$3,050,0003,000,0002.17%
Other shareholders
BIOMARIN PHARMACEUTICAL INC shareholders Q3 2023
NameSharesValueWeighting ↓
SHENKMAN CAPITAL MANAGEMENT INC 30,138,000$29,510,0003.72%
PFM Health Sciences, LP 45,910,000$46,002,0001.72%
Cheyne Capital Management (UK) LLP 2,320,000$2,330,0001.47%
ADVENT CAPITAL MANAGEMENT /DE/ 41,077,000$41,277,0000.66%
SSI INVESTMENT MANAGEMENT LLC 9,071,000$9,068,0000.50%
PALISADE CAPITAL MANAGEMENT, LP 14,548,000$14,612,0000.34%
RWC Asset Management LLP 7,500,000$7,552,0000.21%
KBC Group NV 400,000$40,316,0000.15%
PROSPECTOR PARTNERS LLC 1,000,000$1,000,0000.12%
MACKAY SHIELDS LLC 11,822,000$11,816,0000.10%
View complete list of BIOMARIN PHARMACEUTICAL INC shareholders